Keytruda Resistant TIL and Tumor co-culture

Description

Tumor infiltrating lymphocytes (TILs) are immune cells that have migrated into the tumor environment in order to attach cancer cells. TILs are comprised of immune sub-populations that  play various roles in the immune-tumor interactions.  TILs are removed from a patient’s tumor and are then treated in the laboratory with substances that activate the lymphocytes to help them better kill the patient’s cancer cells (source: NCI).

Using our Keytruda resistant TIL and Tumor cell line, this assay attempts to screen drug candidates in comparison with Keytruda (anti-PD1) therapy.

What is the assay setup?

1. Co-culture tumor and TIL for 24 hours in the presence of drug candidate
2. After 24 hours harvest the supernatants
3. Measure cytokine release and tumor lysis

What are the study arms?

1. TIL + Tumor+ Keytruda (anti-PD1)
2. TIL + Tumor+ <drug candidate (per dose)>
3. TIL + Tumor
4. TIL + Tumor + DMSO
5. TIL
6. Tumor

How many doses are included?

The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.

What is included the price?

• Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
• Assay setup and methods used
• Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.